Alaunos Therapeutics, Inc.
TCRT
$2.63
-$0.05-1.87%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 86.68% | 67.69% | 48.06% | 29.52% | 6.86% |
| Total Depreciation and Amortization | -99.91% | -91.18% | -66.80% | -41.40% | -16.09% |
| Total Amortization of Deferred Charges | -- | -100.00% | -100.00% | -30.92% | 36.49% |
| Total Other Non-Cash Items | -94.27% | -11.60% | 111.91% | 73.98% | 95.42% |
| Change in Net Operating Assets | 88.34% | -118.77% | -11,117.50% | -583.38% | -818.85% |
| Cash from Operations | 83.51% | 60.64% | 41.48% | 26.47% | -3.11% |
| Capital Expenditure | -- | 100.00% | 99.69% | 45.16% | 8.80% |
| Sale of Property, Plant, and Equipment | -- | 2,285.71% | 2,367.21% | 2,367.21% | 6,608.70% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 701.20% | 667.55% | 832.09% | 797.41% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 99.49% | 99.53% | 17.85% | -118.77% |
| Issuance of Common Stock | -- | -100.00% | -100.00% | -100.00% | -99.38% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 200.00% | 200.00% | -- | -- |
| Cash from Financing | -- | 100.00% | 100.00% | -5,832.06% | -384.88% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 89.41% | 74.22% | 61.98% | -8.01% | -103.55% |